Clinical trial
Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS (TRIPS)
Name
TRIPS
Description
The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized, placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe hyperinflammation in children with sepsis-induced multiple organ dysfunction syndrome (MODS).
Trial arms
Trial start
2022-06-14
Estimated PCD
2027-05-15
Trial end
2027-08-31
Status
Recruiting
Phase
Early phase I
Treatment
Anakinra
See information in arm/group descriptions
Arms:
Anakinra 12 mg/kg/day, Anakinra 16 mg/kg/day, Anakinra 4 mg/kg/day, Anakinra 8 mg/kg/day
Placebo
See information in arm/group descriptions
Arms:
Placebo
Size
500
Primary endpoint
Cumulative 28-day Pediatric Logistic Organ Dysfunction (PELOD-2) score
28 days from randomization
Eligibility criteria
Inclusion Criteria:
* ≥ 40 weeks corrected gestational age to \< 18 years; AND
* Admission to the PICU or CICU; AND
* Onset of ≥ 2 new organ dysfunctions within the last 3 calendar days (compared to pre-sepsis baseline) as measured by the modified Proulx criteria; AND
* Documented or suspected infection as the MODS inciting event.
Exclusion Criteria:
* Weight \<3kg; OR
* Limitation of care order at the time of screening; OR
* Patients at high likelihood of progression to brain death in opinion of the clinical team; OR
* Moribund condition in which the patient is unlikely to survive the next 48 hours in opinion of the clinical team; OR
* History of myeloid leukemia, myelodysplasia, or autoimmune thrombocytopenia; OR
* Current or prior diagnosis of hemophagocytic lymphohistiocytosis or macrophage activation syndrome; OR
* Peripheral white blood cell count \< 1,000 cells/mm3 as the result of myeloablative therapyOR receipt of myeloablative therapy within the previous 14 days; OR
* Known allergy to anakinra, or E. coli-derived products; OR
* Known pregnancy; OR
* Lactating females; OR
* Receipt of anakinra or GM-CSF within the previous 28 days; OR
* Resolution of MODS by MODS Day 2; OR
* Previous enrollment in the TRIPS study.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2', 'PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Prospective, adaptively-randomized, double-blind, placebo controlled clinical trial', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 500, 'type': 'ESTIMATED'}}
Updated at
2023-02-08
1 organization
1 product
1 drug
1 indication
Organization
Nationwide Children's HospitalProduct
AnakinraDrug
Varlilumab